20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nuvation Bio Inc (NUVB) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 305 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NUVB reported $63M in revenue and ($205M) in net income.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Interactive charts & full statements → Open the NUVB valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $170M | $63M | $8M | $0M | $0M | $0M | $0M | — | — |
| Gross Profit | $160M | $54M | $1M | $0M | $0M | $0M | $0M | — | — |
| Gross Margin % | 93.9% | 86.6% | 10.1% | — | — | — | — | — | — |
| Operating Income (EBIT) | ($138M) | ($213M) | ($593M) | ($100M) | ($120M) | ($93M) | ($44M) | ($32M) | ($1M) |
| Operating Margin % | -81.0% | -338.7% | -7527.3% | — | — | — | — | — | — |
| Net Income | ($150M) | ($205M) | ($568M) | ($76M) | ($104M) | ($87M) | ($42M) | ($34M) | ($1M) |
| Net Margin % | -88.2% | -325.3% | -7213.8% | — | — | — | — | — | — |
| EBITDA | ($127M) | ($189M) | ($567M) | ($76M) | ($104M) | ($87M) | ($42M) | ($32M) | — |
| Earnings Per Share (EPS) | $-0.44 | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 | $-0.19 | $-0.16 | $-0.01 |
| Shares Outstanding (M) | 349M | 342M | 269M | 219M | 217M | 198M | 218M | 207M | 184M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $32M | $83M | $42M | $13M | $5M | $3M | $6M | $1M |
| Gross Profit | $31M | $78M | $41M | $10M | $2M | $1M | $1M | ($1M) |
| Gross Margin % | 97.1% | 93.2% | 99.0% | 74.5% | 46.7% | 32.1% | 26.2% | -108.4% |
| Operating Income (EBIT) | ($51M) | $4M | ($34M) | ($56M) | ($64M) | ($59M) | ($54M) | ($48M) |
| Operating Margin % | -161.1% | 4.7% | -81.3% | -430.1% | -1315.7% | -1913.2% | -944.5% | -6616.4% |
| Net Income | ($63M) | $5M | ($37M) | ($56M) | ($59M) | ($53M) | ($49M) | ($41M) |
| Net Margin % | -198.3% | 6.5% | -87.4% | -425.2% | -1220.9% | -1726.2% | -865.8% | -5668.5% |
| EBITDA | ($56M) | $13M | ($29M) | ($55M) | ($58M) | ($53M) | ($49M) | ($41M) |
| Earnings Per Share (EPS) | $-0.18 | $0.01 | $-0.11 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.15 |
| Shares Outstanding (M) | 349M | 378M | 344M | 342M | 341M | 339M | 337M | 274M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($83M) | ($173M) | ($130M) | ($68M) | ($96M) | ($68M) | ($37M) | ($24M) | ($1M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $1M |
| Free Cash Flow (FCF) | ($83M) | ($174M) | ($131M) | ($68M) | ($96M) | ($68M) | ($37M) | ($25M) | ($1M) |
| FCF Margin % | -48.8% | -276.3% | -1658.5% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($5M) | $5M | ($30M) | ($53M) | ($48M) | ($43M) | ($46M) | ($31M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($5M) | $5M | ($30M) | ($53M) | ($48M) | ($43M) | ($46M) | ($31M) |
| FCF Margin % | -16.2% | 6.0% | -71.2% | -403.2% | -1000.6% | -1384.5% | -811.0% | -4296.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $745M | $595M | $541M | $621M | $672M | $776M | $222M | $121M | $0M |
| Cash & Cash Equivalents | $259M | $164M | $36M | $43M | $101M | $132M | $30M | $3M | $0M |
| Total Liabilities | $491M | $289M | $77M | $16M | $17M | $30M | $7M | $3M | $1M |
| Total Debt (Short + Long-Term) | $250M | $55M | $8M | $2M | $1M | $1M | $0M | $0M | $1M |
| Total Shareholders' Equity | $254M | $306M | $464M | $605M | $655M | $746M | $215M | $118M | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NUVB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms